5 Key Takeaways

• 1

  Lipase and trypsinogen levels are identified as key biomarkers for distinguishing clinical groups in type 1 diabetes.

• 2

  The study evaluated serum biomarkers from 543 participants aged 2.7 to 30 years, categorized into four clinical groups.

• 3

  Lower lipase levels and higher genetic risk scores were associated with progression from AAb− to ≥2 islet autoantibodies.

• 4

  Recent-onset T1D participants exhibited reduced trypsinogen and elevated lipase compared to those with ≥2 islet autoantibodies.

• 5

  The study emphasizes the need for longitudinal studies to confirm the utility of lipase and trypsinogen in risk stratification.